Loading…
← CockpitCompetitor Analysis › 4568.T Daiichi Sankyo Company LimitedOpen in the cockpit ↗

Daiichi Sankyo Company Limited4568.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharma known for Enhertu, an antibody-drug conjugate for cancer developed with AstraZeneca.

≈ A cancer-focused ADC leader, partnered like Seagen/PfizerMomentum strong 70
Mkt cap
$31.4B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$157M
20-day average traded
Fwd P/E
18.4×
forward earnings
ROIC−WACC
+5.7 pp
WACC 6.7%
Hurdle
-10 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · JPY¥2,778
1D-0.1%
1W+0.3%
1M+0.7%
3M+1.8%
6M+7.9%
YTD-15.9%
1Y-16.5%
ATR %3.5%
52w lowhigh28.1% off high

What Daiichi Sankyo does

Japanese pharma known for Enhertu, an antibody-drug conjugate for cancer developed with AstraZeneca.

Shares the profits and costs of its key cancer drugs with partners, AstraZeneca for Enhertu and datopotamab deruxtecan and Merck for three more drugs agreed in 2023, so it earns through manufacturing payments, profit shares and milestone payments as well as its own sales. Cardiovascular drugs, led by edoxaban, remain the Japanese base.

In one line: A cancer-focused ADC leader, partnered like Seagen/Pfizer.

Products and services

  • Enhertu (ADC, breast/lung/gastric cancer)
  • Other ADC pipeline (datopotamab)
  • Cardiovascular drugs
  • Vaccines

Customers

  • Oncologists and cancer hospitals worldwide

Where it sits in the supply chain

  • Healthcare
  • Biopharmaceuticals
  • Oncology antibody-drug conjugates (ADC)

What could go right

  • Enhertu label expansions
  • New ADC pipeline readouts

What could go wrong

  • ADC competition intensifying
  • Reliance on AstraZeneca partnership economics

Moat: narrow (IP / patents, process know-how). Proprietary ADC linker-payload technology behind Enhertu, licensed globally to AstraZeneca.

Headquarters: Tokyo, Japan · Founded: 1899 · Employees: 20,171

Named competitors

Daiichi Sankyo at a glance

Size Daiichi Sankyo (4568.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $31.4B, the 51st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,778 on 18 Nov 2026.

Performance Over six months the shares gained 7.9%, against +8.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 17.0% over the last twelve months (peer median +17.2%); the operating margin is 12.5% (peer median 18.2%).

Valuation It trades at 18.4× forward earnings against a peer median of 22.9× (9th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.7 points above its cost of capital (6.7% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1124568.T 106
Six months, rebased to 100: Daiichi Sankyo against the median of its 20 peers (local-currency closes).

Daiichi Sankyo financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥2.31T¥2.12T¥1.89T¥1.60T¥1.28T
Revenue growth—+13%+18%+25%—
Gross profit¥1.65T¥1.44T¥1.47T¥1.18T¥915B
EBITDA¥390B¥339B¥377B¥250B¥190B
Net income¥300B¥280B¥296B¥201B¥109B
Free cash flow¥28.3B-¥50.7B-¥62.4B¥511B¥53.8B
Capital expenditure¥144B¥149B¥188B¥123B¥67.4B
Total debt¥500B¥350B¥156B¥156B¥193B

Quarterly statements and history in the cockpit →

Daiichi Sankyo competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%+10%+20%4503DIVISLABZTSROIVBIIBINSM3692RPRXHLN4578INCYSDZVTRSSIG1276688235SUNPHARMAALNYGALD18014568.T6-month return →1-month return →
Up and to the right = strong over both horizons. Daiichi Sankyo is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×4503DIVISLABZTSBIIB3692INCYSDZVTRSSIG688235SUNPHARMAALNYGALD18014568.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Daiichi Sankyo is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%4503DIVISLABZTSBIIB3692RPRX4578INCYSIG688235SUNPHARMAALNYGALD18014568.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Daiichi Sankyo is the large dot.

Daiichi Sankyo competitors and peer comparison

Head to head with its named competitors (4568.T vs 4519.T vs AZN.L vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Daiichi Sankyo 4568.T$31.4B+8%+17%13%18.4×7.6%
Chugai Pharmaceutical 4519.T$75.2B-8%+17%50%23.7×5.0%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Gilead Sciences GILD$210B+30%+7%38%19.9×-2.4%
Roche RO.SW$381B+21%-1%31%19.9×1.7%

How Daiichi Sankyo compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Daiichi Sankyo against its 20 peers (data as of 18 Nov 2026)
Measure4568.TPeer medianRank in peer set
1-month return+0.7%+5.0%7th lowest of 21
6-month return+7.9%+8.9%10th lowest of 21
Distance from 52-week high-28.1%-9.1%5th lowest of 21
Revenue growth (TTM)+17.0%+17.2%11th highest of 21
Operating margin12.5%18.2%6th lowest of 21
Forward P/E18.4×22.9×9th cheapest of 19
Growth the price implies (Req g, 7 yrs)7.6%10.5%7th least demanding of 19
Growth delivered (Del g)+17.1%+9.9%5th highest of 19
Hurdle (Req g minus delivered)-9.5 pp+2.9 pp7th least demanding of 19
ROIC minus cost of capital+5.7 pp+4.8 pp10th highest of 21
EV / EBITDA12.4×22.4×5th cheapest of 18
Net debt / EBITDA-0.5×0.2×9th least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%

Questions

Who are Daiichi Sankyo's main competitors?
Named competitors: Chugai (4519.T), AstraZeneca (AZN.L), Pfizer (PFE), Gilead (GILD), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Astellas Pharma (4503.T), Divi's Laboratories (DIVISLAB.NS), Zoetis (ZTS), Roivant Sciences (ROIV), Biogen (BIIB), Insmed (INSM).
Is Daiichi Sankyo expensive compared with its peers?
On forward p/e it trades at 18.4× against a peer median of 22.9×, 9th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Daiichi Sankyo stock performed?
Over six months to 18 Nov 2026 the shares returned +7.9% against +8.9% for the median peer; over one year -16.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.